Companies: 10,795·Total market cap: $144.5T
PROCEPT BioRobotics Corporation

PROCEPT BioRobotics Corporation

PRCTNASDAQHealthcare● Active
$28.35
+$0.52(+1.87%)
Market Cap$1.6B
P/E Ratio
52W High$66.85
52W Low$19.35
Overview

PROCEPT BioRobotics Corporation (PRCT) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

prct · stock forecast · 15 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 15 Wall Street analysts in the past 3 months

SellBuy

Buy

15 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
11
Hold
3
Sell
1
Strong Sell
0
Total: 15 · Buy rate: 73.3%

12-Month Price Target

High

$62.00

Consensus

$40.25

+41.9% upside

Low

$30.00

Median: $34.5 · Last Close: $28.38

The PROCEPT BioRobotics Corporation (PRCT) analyst consensus is Buy, based on ratings from 15 Wall Street analysts over the past 3 months. The average 12-month PRCT price target is $40.25, representing +41.9% upside from the current price of $28.38.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $40 (41.9%)

Consensus Target

$40.25

41.9% upside

High Target

$62

118.5%

Low Target

$30

5.7%

Current Price

$28.38

as of today

Based on analyst price targets, the PRCT stock price prediction for the next 12 months ranges from $30 to $62. The consensus PRCT price forecast of $40.25 implies 41.9% upside from the current price of $28.38.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$28.430.18%

1-day model range: $28.19–$28.66. Peak: $28.66 (+0.18%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$16-44.1%
2028$12-57.7%
2029$10-63.3%
2030$10-66.0%
2031-67.4%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BULLISH

Based on 14 technical indicators

79%7%14%
11Buy
1Neutral
2Sell
RSI (14)59.5Neutral
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · PRCT · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$27.26BUY
MA 10$27.16BUY
MA 20$27.14BUY
MA 50$25.57BUY
MA 100$26.59BUY
MA 200$30.62SELL
Current $PRCT · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$27.60BUY
EMA 10$27.34BUY
EMA 20$26.92BUY
EMA 50$26.41BUY
EMA 100$27.62BUY
EMA 200$32.68SELL
Current $PRCT · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Piper Sandler2026-04-30
Maintains
OverweightOverweight
Truist Securities2026-03-02
Maintains
BuyBuy
Oppenheimer2026-02-26
Downgrade ↓
OutperformPerform
Wells Fargo2026-02-26
Maintains
OverweightOverweight
B of A Securities2026-02-26
Downgrade ↓
NeutralUnderperform
Leerink Partners2026-02-26
Maintains
OutperformOutperform
Piper Sandler2026-02-26
Maintains
OverweightOverweight
TD Cowen2026-02-26
Maintains
BuyBuy
Truist Securities2025-12-18
Maintains
BuyBuy
B of A Securities2025-12-08
Downgrade ↓
BuyNeutral

Wall Street analysts have recently issued updated ratings on PROCEPT BioRobotics Corporation (PRCT) stock. Of the recent 60 rating actions, 1 were upgrades and 3 were downgrades. 15 analysts currently cover PRCT.

Analyst Recommendation Trends

Buy ratings11
Hold ratings00
Sell ratings00

PRCT analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$399M

↓ 31.8% YoY

Revenue Next Year

$492M

↑ 23.3% YoY

EPS This Year

$-1.53

EPS Next Year

$-0.92

↓ 40.0% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast PRCT EPS of $-1.53 for the current fiscal year, based on estimates from 8 analysts. The PRCT revenue forecast is $399M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The PRCT stock forecast is supported by two independent data sources: analyst consensus ratings from 15 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus PRCT price target is $40.25 (+41.9% upside), with an analyst consensus of Buy.

The PRCT short-term stock prediction for tomorrow is $28.43 (+0.18%). The PRCT stock price prediction for 2027 estimates an average of $16. The PRCT stock prediction for 2030 projects a range of $9–$11.

PROCEPT BioRobotics Corporation trades on NASDAQ under the ticker PRCT. The PRCT stock outlook for 2027 is broadly positive, supported by a Buy consensus among 73% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

PRCT forecast · 8 questions

According to 15 Wall Street analysts, the average 12-month PRCT price target is $40.25, with a high forecast of $62.00 and a low of $30.00. The median price target is shown in the chart above when available. This implies +41.9% potential upside from the current price of $28.38.

PRCT price targetWhat is PRCT price targetPRCT analyst price targetPRCT 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.